Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

2(33%)

Results Posted

100%(3 trials)

Terminated

1(17%)

Phase Distribution

Ph phase_3

17%

Ph not_applicable

17%

Ph phase_4

17%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 2Efficacy & side effects

3(50.0%)

Phase 3Large-scale testing

1(16.7%)

Phase 4Post-market surveillance

1(16.7%)

N/ANon-phased studies

1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(3)

Terminated(1)

Detailed Status

Completed3

Recruiting2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 4

Trials by Phase

Phase 23 (50.0%)

Phase 31 (16.7%)

Phase 41 (16.7%)

N/A1 (16.7%)

Trials by Status

terminated117%

completed350%

recruiting233%

Recent Activity

2 active trials

Showing 5 of 6

recruitingphase_2

The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.

NCT04328480

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT06275919Phase 2

Regorafenib for Recurrent Meningioma (MIRAGE Trial)

Recruiting

NCT05347693Phase 4

Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

Completed

NCT06326190Phase 2

177Lu-DOTATATE for Recurrent Meningioma

Recruiting

NCT02234050Phase 2

Trabectedin for Recurrent Grade II/III Meningioma

Completed

NCT04328480Phase 3

The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.

Completed

NCT03212690Not Applicable

Study of Renin-angiotensin System in Mechanically Ventilated Subjects

Terminated

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6